PROVIGIL (modafinil) tablets, C-IV – prescribing information (2022)

Government Record · Cephalon LLC (labeler); U.S. Food and Drug Administration approved labeling · December 2022

Cephalon LLC (labeler) et al., 2022-12: FDA-approved prescribing information for modafinil (Provigil) confirming that it is a Schedule IV controlled substance.

PROVIGIL contains modafinil, a Schedule IV controlled substance.

Cephalon LLC (labeler) et al., 2022-12: FDA-approved prescribing information for modafinil (Provigil) confirming that it is a Schedule IV controlled substance. C7 (FDA label comparison). Issuer: FDA-approved labeling, marketed by Cephalon LLC. DEA Schedule field in the SPL: CIV. Initial U.S. approval 1998. The same sentence appears in section 9.1 'Controlled Substance'. Record field: structured SPL metadata 'DEA Schedule: CIV' matches the label text. FDA-hosted label PDF for NDA 020717: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020717s037s038lbl.pdf (p. 1). Study type: regulatory record.